EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Klinische Studie (Phase I)Open Access

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma

Jason A Chesney iD, Antoni Ribas iD, Georgina V Long iD, John M Kirkwood iD, Reinhard Dummer iD, Igor Puzanov iD, Christoph Hoeller, Thomas F Gajewski, Ralf Gutzmer iD, Piotr Rutkowski iD, Lev Demidov, Petr Arenberger und 17 weitere

Journal of Clinical Oncology · 20.01.2023 · 41 (3) · 528-540

DOI: 10.1200/jco.22.00343 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.01.2023. Verfasst von Jason A Chesney und 28 weiteren Autor:innen. Beteiligte Einrichtung: UofL Health-Brown Cancer Center, University of Louisville, Louisville, KY. Hauptthemen laut MEDLINE: Melanoma, Oncolytic Virotherapy, Herpesvirus 1, Human. Die Arbeit wurde bisher 322-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The combination of talimogene laherparepvec (T-VEC) and pembrolizumab previously demonstrated an acceptable safety profile and an encouraging complete response rate (CRR) in patients with advanced melanoma in a phase Ib study. We report the efficacy and safety from a phase III, randomized, double-blind, multicenter, international study of T-VEC plus pembrolizumab (T-VEC-pembrolizumab) versus placebo plus pembrolizumab (placebo-pembrolizumab) in patients with advanced melanoma. METHODS Patients with stage IIIB-IVM1c unresectable melanoma, naïve to antiprogrammed cell death protein-1, were randomly assigned 1:1 to T-VEC-pembrolizumab or placebo-pembrolizumab. T-VEC was administered at ≤ 4 × 10 6 plaque-forming unit (PFU) followed by ≤ 4 × 10 8 PFU 3 weeks later and once every 2 weeks until dose 5 and once every 3 weeks thereafter. Pembrolizumab was administered intravenously 200 mg once every 3 weeks. The dual primary end points were progression-free survival (PFS) per modified RECIST 1.1 by blinded independent central review and overall survival (OS). Secondary end points included objective response rate per mRECIST, CRR, and safety. Here, we report the primary analysis for PFS, the second preplanned interim analysis for OS, and the final analysis. RESULTS Overall, 692 patients were randomly assigned (346 T-VEC-pembrolizumab and 346 placebo-pembrolizumab). T-VEC-pembrolizumab did not significantly improve PFS (hazard ratio, 0.86; 95% CI, 0.71 to 1.04; P = .13) or OS (hazard ratio, 0.96; 95% CI, 0.76 to 1.22; P = .74) compared with placebo-pembrolizumab. The objective response rate was 48.6% for T-VEC-pembrolizumab (CRR 17.9%) and 41.3% for placebo-pembrolizumab (CRR 11.6%); the durable response rate was 42.2% and 34.1% for the arms, respectively. Grade ≥ 3 treatment-related adverse events occurred in 20.7% of patients in the T-VEC-pembrolizumab arm and in 19.5% of patients in the placebo-pembrolizumab arm. CONCLUSION T-VEC-pembrolizumab did not significantly improve PFS or OS compared with placebo-pembrolizumab. Safety results of the T-VEC-pembrolizumab combination were consistent with the safety profiles of each agent alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaOncolytic VirotherapyHerpesvirus 1, HumanHumansDouble-Blind MethodBiological ProductsAntibodies, Monoclonal, Humanized

Substanzen

talimogene laherparepvecBiological ProductspembrolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • UofL Health-Brown Cancer Center, University of Louisville, Louisville, KY.
  • Jonsson Comprehensive Cancer Center at the University of California Los Angeles, Los Angeles, CA.
  • Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia.
  • Royal North Shore and Mater Hospitals, Sydney, NSW, Australia.
  • UPMC Hillman Cancer Center, Pittsburgh, PA.
  • University Hospital of Zurich, Zurich, Switzerland.

ORCID-Profile: Jason A Chesney, Antoni Ribas, Georgina V Long, John M Kirkwood, Reinhard Dummer, Igor Puzanov, Ralf Gutzmer, Piotr Rutkowski, Pier Francesco Ferrucci, Andrew Haydon, John Hyngstrom, Sebastian Haferkamp, Josep Malvehy Guilera, Bernardo Leon Rapoport, Ari VanderWalde, Scott J Diede, Helen Gogas

Zitieren

APA

Chesney, J. A., Ribas, A., Long, G. V., Kirkwood, J. M., Dummer, R., Puzanov, I., Hoeller, C., Gajewski, T. F., Gutzmer, R., Rutkowski, P., Demidov, L., Arenberger, P., Shin, S. J., Ferrucci, P. F., Haydon, A., Hyngstrom, J., van Thienen, J. V., Haferkamp, S., Guilera, J. M., …, & Gogas, H. (2023). Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. Journal of Clinical Oncology, 41(3), 528-540. https://doi.org/10.1200/jco.22.00343

Vancouver

Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, et al. Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. Journal of Clinical Oncology. 2023;41(3):528-540. doi:10.1200/jco.22.00343

BibTeX
@article{Chesney2023,
  author = {Chesney, Jason A and Ribas, Antoni and Long, Georgina V and Kirkwood, John M and Dummer, Reinhard and Puzanov, Igor and Hoeller, Christoph and Gajewski, Thomas F and Gutzmer, Ralf and Rutkowski, Piotr and Demidov, Lev and Arenberger, Petr and Shin, Sang Joon and Ferrucci, Pier Francesco and Haydon, Andrew and Hyngstrom, John and van Thienen, Johannes V and Haferkamp, Sebastian and Guilera, Josep Malvehy and Rapoport, Bernardo Leon and VanderWalde, Ari and Diede, Scott J and Anderson, James R and Treichel, Sheryl and Chan, Edward L and Bhatta, Sumita and Gansert, Jennifer and Hodi, Frank Stephen and Gogas, Helen},
  title = {Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {3},
  pages = {528--540},
  doi = {10.1200/jco.22.00343}
}
Kostenlos starten →